Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998

Journal of Clinical Oncology

Volumn 21, Issue 1, 2003, Pages 28-34

  Li, Christopher I ^a   Daling, Janet R ^a   Malone, Kathleen E ^a  

^a Fred Hutchinson Cancer Center and University of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST TUMOR; CARCINOMA; CAUCASIAN; FEMALE; HUMAN; INCIDENCE; METABOLISM; MIDDLE AGED; NEGRO; PATHOLOGY; REGRESSION ANALYSIS; UNITED STATES;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGRESSION ANALYSIS; UNITED STATES;

EID: 0037208632     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2003.03.088     Document Type: Review

References (24)

1. Howe HL, Wingo PA, Thun MJ, et al: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93:824-842, 2001
2. Potter JD, Cerhan JR, Sellers TA, et al: Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: How many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 4:319-326, 1995
3. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer-An overview of the randomised trials. Lancet 351:1451-1467, 1998
4. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326:1756-1761, 1992
5. Clahsen PC, van de Velde CJH, Ducal C, et al: The utility of mitotic index, oestrogen receptor, and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol 25:356-363, 1999
6. Mauri FA, Maisonneuve P, Caffo O, et al: Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2, and PgR expression: An immunohistochemical study on breast carcinoma with long-term follow-up. Int J Oncol 15:1137-1147, 1999
7. Pujol P, Hilsenbeck SG, Chamness GC, et al: Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer 74:1601-1606, 1994
8. Young JL Jr, Percy C, Asire AJ: Surveillance, epidemiology, and end results: Incidence and mortality data, 1973-1977. Natl Cancer Inst Monogr 57:1-1082, 1981
9. McCullagh P, Nelder JA: Generalized linear models. New York, NY, Chapman & Hall, 1989, pp.198-199
10. Gardner W, Mulvey EP, Shaw EC: Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. Psychol Bull 118:392-404, 1995
11. Glynn RJ, Buring JE: Ways of measuring rates of recurrent events. BMJ 312:364-367, 1996
12. Rosner, B: Fundamentals of Biostatistics (ed 4). Belmont, CA, Duxbury Press, 1995, pp. 604-607
13. Enger SM, Ross RK, Paganini-Hill A, et al: Body size, physical activity, and breast cancer hormone receptor status: Results from two case-control studies. Cancer Epidemiol Biomarkers Prev 9:681-687, 2000
14. Huang WY, Newman B, Millikan RC, et al: Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 151:703-714, 2000
15. Trentham-Dietz A, Newcomb PA, Sabatini LM, et al: Hormone replacement therapy and risk of postmenopausal breast cancer according to estrogen and progesterone receptor status. Proc Am Assoc Cancer Res 39:101, 1998
16. Battifora H, Mehta P, Ahn C, et al: Estrogen receptor immunohisto-chemical assay in paraffin-embedded tissue: A better gold standard? Appl Immunohistochem 1:39-45, 1993
17. Yasui Y, Potter JD: The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 10:431-437, 1999
18. Habel LA, Stanford JL: Hormone receptors and breast cancer. Epidemiol Rev 15:209-219, 1993
19. Gapstur SM, Dupuis J, Gann P, et al: Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women: An analysis of 13,239 cases. Cancer 77:1465-1471, 1996
20. Glass AG, Hoover RN: Rising incidence of breast cancer: Relationship to stage and receptor status. J Natl Cancer Inst 82:693-696, 1990
21. Elmore JG, Moceri VM, Carter D, et al: Breast carcinoma tumor characteristics in black and white women. Cancer 83:2509-2515, 1998
22. Wysowski DK, Golden L, Burke L: Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol 85:6-10, 1995
23. Brett KM, Madans JH: Use of postmenopausal hormone replacement therapy: Estimates from a nationally representative cohort study. Am J Epidemiol 145:536-545, 1997
24. National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer-November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001